论文部分内容阅读
目的:通过对比观察有与无胸腺肽α1免疫干预时头颈部肿瘤患者放化疗前、中、后的免疫功能变化,探讨其对头颈部肿瘤患者免疫功能的影响。方法选择50例头颈部肿瘤患者,用随机单盲的方法分为观察组与对照组,均应用FACS Calibur流式细胞仪检测外周血淋巴细胞亚群。观察组患者同步放化疗中进行胸腺肽α1免疫干预。对照组患者进行同步放化疗,无免疫干预。结果两组头颈部肿瘤患者放化疗前、中、后CD3+、CD4+、CD8+、NK细胞均值差异均无统计学意义。观察组综合治疗前后CD4+/CD8+、B细胞均值下降差异无统计学意义。对照组放化疗前后CD4+/CD8+、B细胞均值下降差异有统计学意义,﹤0.05。结论在头颈部肿瘤患者放化疗中,应用胸腺肽α1进行免疫干预能有效预防放化疗导致的机体免疫力下降。“,”Objective To compare the immune function of patients with head and neck cancer before,during and after the comprehensive treatment,when useing thymosinα1 or not.Methods 50 head and neck cancer patients were randomly divided into two groups: observation group(with immunotherapy of thymosin α1) and control group(none immunotherapy). The flow cytometry (FACS Calibur) was used to detect the blood T,B lymphocytes subsets of the two groups.Results In the two groups,patients with head and neck cancer before,during and after the comprehensive treatment CD3+、CD4+、CD8+、NK cel s had no obvious changes. In observation group, CD4+/CD8+ratio and B cel s after treatment had no obvious changes too. In control group, CD4+/CD8+ratio and B cel s after treatment changed significantly( ﹤0.05).Conclusion Immunotherapy with thymosinα1 can ef ectively prevent immunity in the patients with comprehensive treatment from get ing lower.